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Positive effects on mood have been observed in subjects who underwent treatment of glabellar frown
lines with botulinum toxin and, in an open case series, depression remitted or improved after such
treatment. Using a randomized double-blind placebo-controlled trial design we assessed botulinum
toxin injection to the glabellar region as an adjunctive treatment of major depression.
Thirty patients were randomly assigned to a verum (onabotulinumtoxinA, n ¼ 15) or placebo (saline,
n ¼ 15) group. The primary end point was change in the 17-item version of the Hamilton Depression
Rating Scale six weeks after treatment compared to baseline.
The verum and the placebo groups did not differ signiﬁcantly in any of the collected baseline char-
acteristics. Throughout the sixteen-week follow-up period there was a signiﬁcant improvement in
depressive symptoms in the verum group compared to the placebo group as measured by the Hamilton
Depression Rating Scale (F(6,168) ¼ 5.76, p < 0.001, h2 ¼ 0.17). Six weeks after a single treatment scores of
onabotulinumtoxinA recipients were reduced on average by 47.1% and by 9.2% in placebo-treated
participants (F(1,28) ¼ 12.30, p ¼ 0.002, h2 ¼ 0.31, d ¼ 1.28). The effect size was even larger at the end
of the study (d ¼ 1.80). Treatment-dependent clinical improvement was also reﬂected in the Beck
Depression Inventory, and in the Clinical Global Impressions Scale.
This study shows that a single treatment of the glabellar region with botulinum toxin may shortly
accomplish a strong and sustained alleviation of depression in patients, who did not improve sufﬁciently
on previous medication. It supports the concept, that the facial musculature not only expresses, but also
regulates mood states.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Affecting 121 million people, depression is one of the leading
causes of disability in the world (WHO, http://www.who.int/
mental_health/management/depression/deﬁnition/en/). Although
there are various effective treatments, therapy response is
unsatisfactory and depression becomes a chronic condition in
a considerable proportion of patients (Gilmer et al., 2005). Thus,1; fax: þ41 61 325 5585.
llmer).
C-ND license.there is a need to develop further therapeutic techniques to
improve the course and the prognosis of depressive disorders.
Negative emotions, like anger, fear, and sadness, that are prev-
alent in depression are associated with activation of the corrugator
and procerusmuscles in the glabellar region of the face (Ekman and
Friesen, 1978). Accordingly, in patients with depressive disorders
facial electromyography reveals a relative overactivity of the cor-
rugator muscles during different affective imagery paradigms
(Schwartz et al., 1976). Activation of the corrugator muscles is
also correlated with psychomotor agitation in depression and
contributes to facial features like the ‘omega melancholicum’ and
Veraguth’s folds (Greden et al., 1985). Charles Darwin (1872)
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and attributed them to the activity of so-called ‘grief muscles’ in the
glabellar region (Darwin, 1872).
“Refuse to express a passion, and it dies”, this aphorism by
William James (1890) refers to the facial feedback hypothesis,
which implies mutual interaction between emotions and facial
muscle activity (Darwin, 1872; James, 1890). In fact there is exper-
imental evidence that voluntary contraction of facial muscles can
channel emotions, which are conversely expressed by activation of
these muscles (Strack et al., 1988; Larsen et al., 1992).
Injection of botulinum toxin to the glabellar region inhibits the
activity of the corrugator and procerus muscles. This effect is used
in the cosmetic treatment of frown lines (Carruthers and
Carruthers, 1992). Facial treatment with botulinum toxin has
become the most frequent intervention in esthetic medicine with
estimated applications of several million per year (American
Society of Plastic Surgeons Report of the 2010 Plastic Sur-
gery Statistics, http://www.plasticsurgery.org/Documents/news-
resources/statistics/2010-statisticss/Top-Level/2010-US-cosmetic-
reconstructive-plastic-surgery-minimally-invasive-statistics2.pdf).
Treatment of the glabellar region with botulinum toxin
produces a relative change in facial expression from angry, sad,
and fearful to happy and can impact on emotional experience
(Heckmann et al., 2003; Davis et al., 2010). Recipients of this
treatment reported an increase in emotional wellbeing beyond the
cosmetic beneﬁt (Sommer et al., 2003). Speciﬁcally, reduced levels
of fear and sadness were observed (Lewis and Bowler, 2009). The
treatment also attenuated the activation of limbic brain regions
during voluntary contraction of the corrugator and procerus
muscles, indicating that feedback from the facial musculature may
modulate the processing of emotions (Hennenlotter et al., 2009).
Hence, the processing time for sentences with negative affective
connotation was prolonged in women after glabellar botulinum
toxin treatment and the treatment interfered with the ability to
decode the facial expression of other people (Havas et al., 2010;
Neal and Chartrand, 2011). The capacity of this intervention to
counteract negative emotions may also be of clinical use.
Accordingly, preliminary data from an open case series with ten
female patients indicate that it may reduce the symptoms of
depression (Finzi and Wasserman, 2006). We hypothesized that
facial psychomotor features associated with depression are not
just epiphenomena but integral components of the disorder and
may be targeted in its therapy. To explore, if attenuation of these
features may produce alleviation in the affective symptoms, we
conducted a randomized controlled trial of botulinum toxin
injection to the glabellar region as an adjunctive treatment of
major depression.2. Materials and methods
2.1. Trial design
At two centers, the Psychiatric University Hospital of the
University of Basel, Switzerland and the Medical School Hannover,
Germany we conducted a randomized, placebo-controlled, double-
blind trial from August 2009 through October 2010. The trial has
been registered with ClinicalTrials.gov, number, NCT00934687. The
study was investigator-initiated and was carried out independently
of any commercial entity. It was funded solely by the Gottfried &
Julia Bangerter-Rhyner-Stiftung, Bern, Switzerland, a private foun-
dation that supports medical research (http://www.bangerter-
stiftung.ch/). The study protocol was approved by the institu-
tional review boards, the local ethic committees and the Swiss and
German regulatory authorities. It comprised seven visits (baseline,two weeks, four weeks, six weeks, eight weeks, twelve weeks, and
sixteen weeks after baseline).
A power analysis based on the observations from the open case
series (Finzi and Wasserman, 2006), allowing for an equal placebo
control group with a theoretical 50% improvement, indicated that
a sample size of <30 participants would be sufﬁcient to detect
comparable effects with a power of >80% at a signiﬁcance level of
p < 0.05.
2.2. Participants
Participants were recruited from local psychiatric outpatient
units, psychiatrists in private practice, or through advertisements
placed in the local press. The method under investigation, i.e.
botulinum toxin treatment, was not explicitly mentioned in the
advertisement, in order to avoid attracting candidates who were
primarily motivated by receiving this treatment for cosmetic
reasons. Both men and women were included. Inclusion criteria
were: age 25e65 years, on-going major depressive disorder (DSM-
IV 296.xx) diagnosed according to the Structured Clinical Interview
for Axis I DSM-IV disorders (SCID I; 15 points on the Hamilton
Depression Rating Scale at screening) with or without a history of
dysthymic disorder (DSM-IV 300.4), and a moderate to severe
vertical glabellar line during maximum voluntary frowning
according to a four-point clinical severity score (Honeck et al.,
2003) as well as qualitatively and quantitatively stable treatment
with one or, at most, two antidepressants for at least four weeks.
For ethical reasons we did not include untreated patients unless
they had not responded to at least one treatment trial with an
antidepressant during on-going index episode and were reluctant
to undergo another one.
Exclusion criteria were: psychotic symptoms, suicidal tendency,
clinical severity requiring immediate intervention, further DSM-IV
axis I diagnoses, clinically manifest personality disorder, severe
premenstrual syndrome or premenstrual dysphoric syndrome,
regular occurrence of migraine or other forms of cephalalgia,
psychological strain associated with glabellar frown lines, contra-
indications of botulinum toxin treatment, previous treatment with
botulinum toxin, further psychopharmacological treatment other
than a demand medication with limited amounts of sedatives or
hypnotics (lorazepam up to 4 mg/week, oxazepam, up to 60 mg/
week, zolpidem up to 20mg/week, or zopiclone up to 15mg/week),
and on-going disorder-speciﬁc psychotherapy or any other speciﬁc
therapy of depression.
From all participants we collected psychopathological ﬁndings
and a personal, medical, and psychiatric history. Response to anti-
depressant treatment during on-going index episode was assessed
according to the Massachusetts General Hospital Antidepressant
Treatment Response Questionnaire (MGH-ATRQ; Fava and
Davidson, 1996). Treatment resistance was rated on a graduated
scale (Thase and Rush, 1997). Participants were subjected to
a general physical and neurological examination. Complementary
somatic diagnostic procedures were disposed if organic reasons for
depression had not been sufﬁciently excluded previously. All
patients provided written informed consent after complete
description of the study and before inclusion. Participants promised
to leave their antidepressant medication unchanged during the ﬁrst
six weeks of the trial. Thereafter, they were allowed to change their
treatment in consultation with their physician.
2.3. Interventions
For the verum condition onabotulinumtoxinA (Vistabel,
Botox Cosmetic, Allergan) was dissolved in 0.9% NaCl solution (B.
Braun Medical) at a concentration of 100U/2.5 ml. Injections were
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in the glabellar region (Supplemental Fig. 1). Women received 29 U
of onabotulinumtoxinA in total. We injected 7 U to the procerus
muscle, 6 U bilaterally to the medial part of the corrugator muscles,
and 5 U bilaterally to the lateral part of the corrugator muscles. The
same injection scheme was applied in the open case series (Finzi
and Wasserman, 2006). To account for their higher muscle mass,
men received twomore units at each injection site, i.e. 39 U in total.
For the placebo condition we injected identical volumes of 0.9%
NaCl solution according to the described injection scheme. The
intervention took place once at the end of the baseline visit.
2.4. Outcomes
At each study visit participants were assessed using the
following instruments and measures: The validated German
translation of the Structured Interview Guide for the Hamilton
Depression Rating Scale with Atypical Depression Supplement
(SIGH-ADS) (Williams and Terman, 2003), the Beck Depression
Inventory (BDI) self-rating questionnaire, the Clinical Global
Impressions Scale (CGI), the four-point Clinical Severity Score for
Glabellar Frown Lines (CSS-GFL) (Honeck et al., 2003), a standard-
ized photograph of the face during maximum frowning, and an
inquiry regarding side effects and changes in concomitant treat-
ment. SIGH-ADS and CGI raters were experienced psychiatrists and
clinical psychologists. A rater training held in preparation of the
study yielded a high inter-rater reliability for the SIGH-ADS
(intraclass correlation coefﬁcient, ICC(3,1) ¼ 0.97). If possible,
participants were examined by the same raters throughout the
entire study.
The primary end point of the trial was change in the 17-item
version of the Hamilton Depression Rating Scale (HAM-D17) score
at the visit after six weeks versus baseline. The clinical response
measured by the HAM-D17 score was classiﬁed as nonresponse
(<25% reduction), partial response (25%e49% reduction), response
(50% reduction), or remission (HAM-D17 score 7).
2.5. Randomization and blinding
Participants were randomized using a computer-generated
(Software R, R Development Core Team) randomization list
comprising one block with 30 positions and a pre-deﬁned alloca-
tion ratio of 1:1. It was provided by the Clinical Trial Unit of the
University of Basel and was administered by a physician who was
not otherwise involved in the study. When a new participant was
included he randomized the participant according to the running
number of the randomization list and instructed the study nurse of
the respective center to prepare verum or placebo injections. The
drug account was administered by the study nurse.
Syringes prepared for verum or placebo injection were optically
indistinguishable from each other. Participants were instructed that
the extent and the kinetics of the paralytic onabotulinumtoxinA
effect were inter-individually variable and that the injection of
saline may induce a temporary reduction in frown lines, owing to
swelling of the treated area. To conceal cosmetic changes from
psychometric raters, participants wore an opaque surgical cap,
which covered glabella and forehead during the examinations.
Assessment and photo documentation of glabellar frown lines, as
well as assessment of local side effects, were conducted by other
study personnel. Participants did not receive a feedback on
cosmetic changes. At the end of the trial we asked participants and
psychometric raters to guess group allocation in a forced decision
and on a graduated scale (Bang et al., 2004). Because these factors
may have an inﬂuence on placebo effects, we asked participants to
rate treatment expectancy and rationale credibility according toa credibility/expectancy questionnaire (Devilly and Borkovec,
2000). Moreover, participants were asked for an appraisal of their
cosmetic change on a ﬁve point Likert scale (0 ¼ very negative,
1 ¼ somewhat negative, 2 ¼ neutral, 3 ¼ somewhat positive,
4 ¼ very positive).
2.6. Statistical analyses
Data were analyzed using two-way analyses of variance
(ANOVA) for repeated measures with the factors group (verum vs.
placebo) and time (seven time points throughout the sixteen-
week follow-up period as well as two time points, baseline and
six weeks after baseline, for the primary end point). In the case
of deviation from sphericity, ANOVAs were performed using
GreenhouseeGeisser ( 3) corrected degrees of freedom. Inner
subject effects of time by group interactions are reported. Where
appropriate, post-hoc tests with a BonferronieHolm adjustment
were used, applying Student’s t-tests or, in the case of variance
inhomogeneity, the more robust Welch-test. These tests were also
applied for continuous baseline variables. For categorical variables
Fisher’s exact tests were employed. All tests were two-sided.
Variance is reported as standard deviation (SD) unless otherwise
noted. Effect sizes are reported as partial h2, Cohen’s d, or odds
ratio (OR). To assess linear relationship between scales, Pearson’s
correlation coefﬁcients (r) were calculated. Test results with an
alpha level 0.05 are reported as signiﬁcant. Statistical analyses
were conducted using SPSS 19.0 for Windows.
3. Results
3.1. Participant ﬂow and baseline characteristics
We assessed 263 subjects for eligibility in order to include the
pre-deﬁned number of 30 participants. Only ten patients were
referred to the study by their physicians. Among these patients the
yield ratewas 60%. In detail, one participant was recruited by a local
psychiatric outpatient unit and ﬁve were recruited via psychiatrists
in private practice. The remaining 24 participants were included
through advertisements in the local press. As expected, this
strategy was associated with a much lower yield rate (9.5%). The
major causes for exclusion were psychiatric comorbidity and
medication, and declining to follow the study protocol. Six subjects
speciﬁcally refused to undergo onabotulinumtoxinA treatment and
three subjects could not be included only because they were not
able to produce an at least moderate glabellar line at maximum
frowning. Once randomized, all participants received the allocated
intervention and completed the trial up to the ﬁnal visit. The
investigators consistently reminded andmotivated the participants
to follow the study protocol and come to the visits. Thus, therewere
no dropouts or protocol violations and no participant had to be
excluded from the analysis (CONSORT diagram, Supplemental
Fig. 2).
Verum and placebo groups did not differ signiﬁcantly in any of
the demographic or clinical baseline variables (Table 1).
3.2. Efﬁcacy outcomes
Over the seven time points throughout the sixteen-week
duration of the trial the following observations were made:
Glabellar frown lines at maximum frowning were attenuated by
almost one point on the four-point Clinical Severity Score for
Glabellar Frown Lines, CSS-GFL, in the verum group. This effect
occurred within two weeks, remained constant until the visit after
eight weeks and started to wear off slightly thereafter. In contrast
CSS-GFL remained unchanged in the placebo group (ANOVA,
Table 1
Baseline characteristics of study participants, verum (onabotulinumtoxinA) vs. placebo.
Variable Total (N ¼ 30) Verum (N ¼ 15) Placebo (N ¼ 15) Test Signiﬁcance
Demographic data
N % N % N %
Women 23 76.7 12 80.0 11 73.3 Fisher’s exact p ¼ 1.00
Living alone 14 46.7 5 33.3 9 60.0 Fisher’s exact p ¼ 0.27
Centre Basel 13 43.3 6 40.0 7 46.7 Fisher’s exact p ¼ 1.00
Mean SD Mean SD Mean SD df
Age, years 50.57 8.91 52.2 7.54 48.93 10.10 t ¼ 1.00 28 p ¼ 0.32
Education, years 13.50 2.35 14.07 2.40 12.93 2.22 t ¼ 1.34 28 p ¼ 0.19
BMI 26.76 7.72 26.83 7.62 26.68 8.08 t ¼ 0.05 28 p ¼ 0.96
Speciﬁcation of depression
N % N % N %
Recurrent F33.xx 24 80.0 11 73.3 13 86.7 Fisher’s exact p ¼ 0.65
Moderate F3x.1x 20 66.7 11 73.3 9 60.0 Fisher’s exact p ¼ 0.70
Somatic syndrome F3x.x1 16 53.3 9 60.0 7 46.7 Fisher’s exact p ¼ 0.72
History of dysthymic disorder 8 26.67 3 20.0 5 33.3 Fisher’s exact p ¼ 0.68
Chronic IE 13 43.3 6 40.0 7 46.7 Fisher’s exact p ¼ 1.00
Mean SD Mean SD Mean SD df
Duration of MDD, years 16.03 12.67 16.40 11.97 15.67 13.74 t ¼ 0.16 28 p ¼ 0.88
Duration of IE, months 28.53 28.01 26.40 28.60 30.67 28.23 t ¼ 0.41 28 p ¼ 0.68
Number of episodes 7.13 9.12 9.07 12.27 5.20 3.71 t ¼ 1.17 28 p ¼ 0.25
HAM-D17 20.07 4.37 21.40 4.31 18.73 4.15 t ¼ 1.73 28 p ¼ 0.10
HAM-D21 22.23 4.29 23.27 3.83 21.20 4.60 t ¼ 1.34 28 p ¼ 0.19
ADS 7.53 4.18 8.80 4.16 6.27 3.92 t ¼ 1.72 28 p ¼ 0.10
SIGH-ADS 27.60 7.42 30.20 7.58 25.00 6.49 t ¼ 2.02 28 p> 0.05
BDI 25.33 8.14 27.00 8.91 23.67 7.21 t ¼ 1.13 28 p ¼ 0.27
CGI 4.50 0.73 4.67 0.62 4.33 0.82 t ¼ 1.26 28 p ¼ 0.22
Antidepressant medication
N % N % N %
SSRI 10 33.3 6 40.0 4 26.7 Fisher’s exact p ¼ 0.70
SNRI 9 30.0 4 26.7 5 33.3 Fisher’s exact p ¼ 1.00
Mirtazapine 6 20.0 1 6.7 5 33.3 Fisher’s exact p ¼ 0.17
Tricyclic compounds 6 20.0 4 26.7 2 13.3 Fisher’s exact p ¼ 0.65
Other compounds 6 20.0 2 13.3 4 26.7 Fisher’s exact p ¼ 0.65
Combination 8 26.7 3 20.0 5 33.3 Fisher’s exact p ¼ 0.68
Mean SD Mean SD Mean SD df
Treatment trials during IE 1.27 0.69 1.40 0.83 1.13 0.52 t ¼ 1.06 28 p ¼ 0.30
Treatment resistance stage 0.83 0.65 1.00 0.66 0.67 0.62 t ¼ 0.93 28 p ¼ 0.36
Current antidepressants 1.23 0.50 1.13 0.52 1.33 0.49 t ¼ 1.09 28 p ¼ 0.29
Adequate dose 1.03 0.56 1.00 0.54 1.07 0.59 t ¼ 0.32 28 p ¼ 0.75
Stable treatment, months 19.35 20.68 18.30 15.82 20.46 25.48 t ¼ 0.28 28 p ¼ 0.78
Further characteristics
CSS-GFL 2.33 0.48 2.20 0.41 2.47 0.52 w ¼ 1.56 28 p ¼ 0.13
SCID II 4.04 2.33 3.71 2.40 4.36 2.31 t ¼ 0.73 26 p ¼ 0.48
Besides those formajor depressive disorder (DSM-IV 296.xx) all participants also fulﬁlled the ICD-10 criteria for mild tomoderate depressive episode. Depressionwas speciﬁed
according to ICD-10 (F32.00-F33.11). Chronic duration of on-going index episode (IE) was deﬁned as 24 months. ADS is the score for atypical depression symptoms, SIGH-
ADS is the sum score of HAM-D17 þ ADS. SSRI (selective serotonin reuptake inhibitors), SNRI (serotonin and noradrenalin reuptake inhibitors), mirtazapine, tricyclic
compounds, and other compounds (bupropion, moclobemide, trazodone, or St. John’s wort extract) refer to the number of participants treated with the respective medication.
Combination indicates the number of participants treated with two antidepressants. Treatment resistance was staged according to Thase and Rush, 1997. Adequate dose is the
number of current antidepressants given in at least the smallest recommended dose for the treatment of major depression. SCID II is the number of traits in the Structured
Clinical Interview for Axis II DSM-IV disorders (SCID II) questionnaire with above threshold scores. Clinical evaluation of these ﬁndings did not result in the diagnosis of
a manifest personality disorder in any of the study participants. Elevated scores were rather owing to the in most cases longstanding depressive disorder, which made it
difﬁcult for the patients to differentiate between depression-related states and personality traits. For Welch-test uncorrected degrees of freedom (df) are reported. All
statistical tests were two-sided. There was a trend towards higher SIGH-ADS scores in the verum group (p ¼ 0.053). Introduction of the SIGH-ADS score at baseline as
a covariate did not in principle change the results of the ANOVAs (data not shown).
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Fig. 1A). There was a signiﬁcant clinical improvement in depres-
sion over time in the verum group, but not in the placebo one. Apart
from a ﬂuctuation at the visit after eight weeks this effect increased
until the ﬁnal visit. It was measured by the Hamilton Depression
Rating Scale, HAM-D17, score (ANOVA, n ¼ 30; F(6,168) ¼ 5.76,
3¼ 0.74, h2 ¼ 0.17, p < 0.001, two-sided; Fig. 1B) and by the Beck
Depression Inventory, BDI, score (ANOVA, n ¼ 30; F(6,168) ¼ 3.79,
3¼ 0.51, h2 ¼ 0.12, p ¼ 0.01, two-sided; Fig. 1C) and was also
reﬂected in an improvement in the Clinical Global ImpressionsScale, CGI, (ANOVA, n ¼ 30; F(6,168) ¼ 7.91, 3¼ 0.66, h2 ¼ 0.22,
p < 0.001, two-sided; Fig. 1D). The external rating (HAM-D17) and
the self-assessment (BDI) of depression symptoms were correlated
(Pearson’s product moment correlational analysis, n ¼ 30; r ¼ 0.75,
p < 0.001).
As for the primary end point (HAM-D17 at the visit after six
weeks versus baseline), there was a signiﬁcant improvement in the
verum group compared to the placebo groupwith a large effect size
(10.07  8.16 points, 47.1% vs. 1.73  4.25 points, 9.2%;
ANOVA, Student’s t-test, n ¼ 30; F(1,28) ¼ 12.30, h2 ¼ 0.31,
CSS-GFL
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Fig. 1. Efﬁcacy outcomes are presented as score changes (mean  standard error, SEM) in the CSS-GFL (A), HAM-D17 (B), the BDI (C), and the CGI (D) In the onabotulinumtoxinA
group (n ¼ 15) and the placebo group (n ¼ 15) at the visits after two, four, six, eight, twelve, and sixteen weeks versus baseline (set to zero). P-values refer to inner subject effects of
time by group interactions from ANOVAs with GreenhouseeGeisser-corrected degrees of freedom. Asterisks indicate time points with signiﬁcant group differences in post-hoc tests
after Bonferroni-Holm adjustment of p-values for initially six comparisons (*p  0.05, **p  0.01, ***p  0.001). All participants were included and all statistical tests were two-sided.
All values and detailed statistics corresponding to the graphs are available in the supplemental data section (Supplemental table 1). Between the visit after eight weeks and the visit
after sixteen weeks eleven participants underwent some change in their treatment. Nine of these changes were counteractive to the group difference, i.e. intensiﬁcations of therapy
in the placebo group or cutback of therapy in the verum group. Exclusion of the participants with treatment changes did not in principle affect the group differences observed in the
last two visits or inﬂuence the run of the HAM-D17, BDI, and CGI curves (data not shown).
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partial response rate (25%e49% HAM-D17 score reduction; 86.7% vs.
26.7%; Fisher’s exact test, n ¼ 30; OR ¼ 17.9, 95% CI ¼ 2.7e116.9,
p ¼ 0.003, two-sided) and the response rate (50% HAM-D17Table 2
Efﬁcacy outcome measures six weeks after baseline.
Variable Verum (N ¼ 15) Placebo (N ¼ 15)
Mean SD Mean SD
CSS-GFL 1.33 0.62 2.40 0.63
HAM-D17 11.33 7.22 17.00 6.52
HAM-D21 12.47 7.76 18.53 6.84
ADS 6.00 5.18 6.27 1.94
SIGH-ADS 17.33 11.27 23.27 7.41
BDI 16.33 11.55 24.47 11.41
CGI 3.27 1.33 4.40 0.99
Differen
D CSS-GFL 0.87 0.35 0.07 0.26 0.8
D HAM-D17 10.07 8.16 1.73 4.25 8.34
D HAM-D21 10.80 8.87 2.67 4.69 8.13
D ADS 2.80 2.96 0.00 3.66 2.80
D SIGH-ADS 12.87 10.32 1.73 6.92 11.14
D BDI 10.67 10.77 0.80 7.06 11.47
D CGI 1.40 1.24 0.07 0.70 1.47
The table reports the scores at the visit after six weeks and the D values between this vis
weeks after baseline (df¼ 1,28). Effect sizes are reported as partial h2 and Cohen’s d, refer
or Welch-tests (df ¼ 28) of D values, respectively. All statistical tests were two-sided. Thscore reduction; 60.0% vs. 13.3%; Fisher’s exact test, n ¼ 30;
OR¼ 9.8, 95% CI¼ 1.6e59.7, p¼ 0.02, two-sided) were signiﬁcantly
higher in the verum group than in the placebo one (Fig. 2). Of the
collected baseline characteristics only female sex was signiﬁcantlyTest Effect size Signiﬁcance
F ¼ 50.40 h2 ¼ 0.64 p < 0.001
F[ 12.30 h2 [ 0.31 p[ 0.002
F ¼ 9.87 h2 ¼ 0.26 p ¼ 0.004
F ¼ 5.30 h2 ¼ 0.16 p ¼ 0.029
F ¼ 12.05 h2 ¼ 0.30 p ¼ 0.002
F ¼ 11.88 h2 ¼ 0.30 p ¼ 0.002
F ¼ 15.83 h2 ¼ 0.36 p < 0.001
ce CI
1.02 to 0.58 t ¼ 7.10 d ¼ 2.59 p < 0.001
L13.00 to L3.68 t[ 3.51 d[ 1.28 p[ 0.002
13.21 to 3.05 t ¼ 3.14 d ¼ 1.14 p ¼ 0.004
5.18 to 0.42 t ¼ 2.30 d ¼ 0.84 p ¼ 0.029
17.43 to 4.85 t ¼ 3.47 d ¼ 1.27 p ¼ 0.002
17.99 to 4.95 t ¼ 3.45 d ¼ 1.26 p ¼ 0.002
2.19 to 0.75 w ¼ 3.98 d ¼ 1.46 p < 0.001
it and the baseline. ANOVAs were calculated with two time points, baseline and six
ring to ANOVA inner subject effects of time by group interactions and Student’s t-test
e primary end point is highlighted in bold type.
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Fig. 2. Partial response, response, and remission rates are presented as number and
percentage of participants in the onabotulinumtoxinA group and the placebo group at
the visit after six weeks. Signiﬁcant group differences were observed for partial
response (** Fisher’s exact, p¼0.003, OR¼17.9, 95% CI¼2.7e116.9) and response (*
Fisher’s exact, p¼0.02, OR¼9.8, 95% CI¼1.6e59.7). Originally, response rate deﬁned as
a 30% reduction in the HAM-D score was registered as the primary end point
(ClinicalTrials.gov, NCT00934687), which is obviously also positive. For reasons of
comparability with other studies it was changed to the primary end point described in
the text.
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two-sided; Supplemental Table 2). Hence, differences between
the verum and the placebo group were slightly more pronounced,
when the primary end point was analyzed for female
participants alone (11.67  7.48 points, 53.9% vs. 2.36  4.37
points, 13.0%; ANOVA, Student’s t-test, n ¼ 23; F(1,21) ¼ 12.95,
h2 ¼ 0.38, t(21) ¼ 3.60, d ¼ 1.52, p ¼ 0.002, two-sided). Even larger
effect sizes were observed at the end of the sixteen-week follow-up
period (HAM-D17, whole sample d ¼ 1.80; Supplemental Table 3;
female participants d ¼ 2.32).
3.3. Side effects and blinding quality
The study treatment was well tolerated. Apart from local irri-
tation immediately after injection, short episodes of headache
during the ﬁrst weeks were the only relevant and possibly
treatment-related adverse events during the trial. They occurred
both in the verum and in the placebo group (40.0% vs. 26.7%,
Fisher’s exact, p ¼ 0.7).
At the end of the trial 90% of the participants guessed their group
allocation correctly with ﬁrm conviction. They named presence or
absence of cosmetic change as the major unblinding factor.
Psychometric raters guessed 60% of group allocations correctly.
They were less convinced about their guesses and improvement
in depressive symptoms or lack of it was the major clue.
Treatment expectancy and rationale credibility ratings did not
differ between groups at baseline and did not predict clinical
outcome (Supplemental Table 2). Treatment response was not
associatedwith the appraisal of the cosmetic change (Supplemental
Table 2).
4. Discussion
In the present study, we show, for the ﬁrst time using
a randomized controlled trial design, that a single treatment of the
glabellar region with onabotulinumtoxinA may reduce the
symptoms of major depression. This effect developed within few
weeks and persisted until the end of the sixteen-week follow-up
period. The effect sizes in our study were large and the response
and remission rates were high for a trial with patients suffering
from partly chronic and treatment resistant depression (Rush
et al., 2006).Botulinum toxin treatment offers some favorable characteris-
tics: The long-running effect of a single dose may circumvent
problems associated with poor therapy adherence, which is a crit-
ical issue in the treatment of depressed patients (Serna et al., 2010).
Because of the long treatment intervals it may also be an economic
treatment option (Beer, 2010). Moreover, the safety and tolerability
record of botulinum toxin injections to the glabellar region is
excellent (Brin et al., 2009).
It is unknown how botulinum toxin ameliorates depression.
Several mechanisms may be involved: We assume that reduced
proprioceptive feedback from the paralyzed facial muscles is
a relevant mechanism of mood improvement. This mechanism is
supported by other studies that show effects of botulinum toxin
treatment on emotional perception (Hennenlotter et al., 2009;
Havas et al., 2010; Neal and Chartrand, 2011), as well as by exper-
iments in which facial muscle activity was inﬂuenced by other
means (Strack et al., 1988; Larsen et al., 1992). Thus, botulinum
toxin treatment may act comparable to a passive and uninterrupted
relaxation exercise. It is possible that a more positive facial
expression and improved feedback both from one’s own face in the
mirror and from social interaction partners may have contributed
to mood enhancement (Heckmann et al., 2003). We largely exclude
a merely esthetic beneﬁt as the major cause of mood improvement,
because we did not include patients who were cosmetically con-
cerned about their frown lines. Notably, treatment response did not
depend on a positive appraisal of the cosmetic change. One
participant actually attained remission but disliked the change in
facial appearance. Animal studies have shown that retrograde
axonal transport of botulinum toxin is possible (Antonucci et al.,
2008). Thus, we cannot exclude involvement of central pharma-
cological botulinum toxin effects including possible pharmacody-
namic or pharmacokinetic interactions with the concomitant
antidepressant therapy.
Placebo effects play a relevant part in the clinical improvement
in depression under therapy and we assume that they also
contribute to the clinical change observed in the present study
(Brunoni et al., 2009; Rief et al., 2009). The method-immanent
cosmetic effect of onabotulinumtoxinA treatment entailed a high
unblinding rate among participants. This may have caused a bias in
placebo effects in favor of the verum group, leading to underesti-
mation of the placebo proportion of clinical improvement.
However, high unblinding rates are common in antidepressant
trials and a recent study shows that open-label placebo treatment
can still induce clinical improvement (Perlis et al., 2010; Even et al.,
2000; Kaptchuk et al., 2010). This is also in line with the substantial
improvement observed in the placebo arm of the PREEMPT study,
which recently led to registration of onabotulinumtoxinA injections
to the head-neck area, including the glabellar region as treatment
for chronic migraine (Dodick et al., 2010). Notably, one participant
in the verum group of our study whose structurally ﬁxed frown line
persisted after treatment was convinced to be on placebo, but still
attained remission of depression. Unblinding of psychopathological
raters was below the range reported in other antidepressant trials
(Even et al., 2000). It arose from treatment outcome rather than
predicted it. Thus, it is unlikely that observer-expectancy effects
may have accounted for a large proportion of the group difference.
The improvement we observed in the placebo group was only
marginal and fell short of our expectations. This may be ascribed to
the high proportion of participants with a long duration of
depression and poor response to previous treatment (Brown et al.,
1992). Although the two groups of our study did not differ signif-
icantly in any of the collected baseline variables, we cannot fully
exclude that hidden selection biases may have contributed to the
particularly small improvement in the placebo group and a conse-
quential inﬂation of the outcome differences between the groups.
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in larger trials. It has some limitations that should be addressed:
The proportion of male participants was too low to make a state-
ment on efﬁcacy in men; however, there may be a gender effect in
favor of women. Generalizability is also limited by the selection of
patients with glabellar frown lines, although only three subjects
were excluded owing to lack of these lines. It is unclear, whether
the treatment can also alleviate depression in hypomimic patients
without this psychomotor phenotype. In our study onabotuli-
numtoxinAwas applied essentially as an adjunctive intervention in
patients with stable pharmacological therapy. Therefore, it is
possible that botulinum toxin is not an antidepressant per se but
may rather augment the antidepressant effect of the concomitant
medication. However, one participant in the verum group was
devoid of any antidepressant medication and still attained remis-
sion. Remission of participants without previous or present anti-
depressant medication also occurred in the open case series (Finzi
andWasserman, 2006). In spite of these observations, it remains to
be established, whether botulinum toxin is also effective as
a primary intervention in treatment-naïve patients. Moreover, it is
uncertain if patients with severe or bipolar depression will beneﬁt
from botulinum toxin treatment. One theoretical hazard of the
method is that modiﬁcation of facial expression may conceal
psychological strain in patients who do not respond or have not yet
responded psychopathologically.
Sad facial expression is not only conferred by muscles of the
glabellar region but also by muscles in lower sections of the face. It
is possible that treatment of the depressor angulis oris and the
mentalis muscles, for example, may also have mood-elevating
effects and may enhance the clinical effect of the glabellar injec-
tion of botulinum toxin. Modulation of mood states with botulinum
toxin may also be effective in the treatment of other clinical
conditions involving negative emotions, like anxiety disorders.
In summary our study provides new evidence that botulinum
toxin injection to the glabellar region may be an effective, safe, and
sustainable intervention in the treatment of depression. It provides
clinical support for the concept that the facial musculature not only
expresses, but also regulates, mood states. At this juncture, the
indication-compatible treatment of dynamic glabellar rhytides
with botulinum toxin may be considered for depressed patients
with the objective of inducing mood-lifting side effects.
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